HNWAG
ADAP

High Net Worth Advisory Group’s Adaptimmune Therapeutics ADAP Stock Holding History

High Net Worth Advisory Group’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,000
Closed -$4K – 681
2021
Q4 		$4K Buy
+1,000
New +$4.55K ﹤0.01% 614

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

High Net Worth Advisory Group's ADAP Position: Q1 2022 in Review

High Net Worth Advisory Group sold out of Adaptimmune Therapeutics (ADAP) in Q1 2022, closing a stake of 1,000 shares — an estimated $4K sold.

High Net Worth Advisory Group first reported a position in ADAP in Q4 2021 and held it in 1 quarter. The position peaked at $4K in Q4 2021. 80 funds tracked by Wall St. Rank hold ADAP as of Q1 2022.

  • High Net Worth Advisory Group reported no remaining Adaptimmune Therapeutics position as of Q1 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 1,000 Adaptimmune Therapeutics shares in Q1 2022, an estimated $4K.
  • High Net Worth Advisory Group first reported a position in Adaptimmune Therapeutics in Q4 2021 and held it in 1 quarter.
  • High Net Worth Advisory Group's Adaptimmune Therapeutics position peaked at $4K in Q4 2021.
  • 80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2022.

Based on High Net Worth Advisory Group's 13F filing for Q1 2022, filed 13 May 2022.